Novel compounds. High stakes. No room for weak evidence.
Novel mechanisms, high stakes
Regulatory scrutiny on psychedelics demands bulletproof evidence. Phase 2/3 trials are expensive. A weak hypothesis wastes years.
Citation integrity under pressure
An analysis reported by Retraction Watch in May 2026 found fabricated references in about 1 in 277 PubMed-indexed papers from early 2026. One bad citation in a grant or paper can sink it.
Hypothesis explosion
Ketamine, psilocybin, MDMA — mechanisms multiply faster than lab capacity. Need adversarial review before committing resources.
Source: Retraction Watch, 7 May 2026, reporting a Lancet letter on fabricated references in PubMed-indexed papers.
Adversarial verification before you commit.
Multi-model adversarial pipeline
One model synthesizes. Another attacks. A third checks evidence. Weak candidates are rejected before delivery.
Verified citations
Every DOI checked against live databases. No hallucinated references reach your output.
1,538-paper corpus
Psychedelics-mental-health domain. PubMed-sourced. Indexed for mechanism, compound, and outcome.
What the pipeline produces.
mGlu2/3 receptor agonism for treatment-resistant depression: Pipeline ingested 1,538 papers. Generated 21 candidate hypotheses. Critic rejected 20 on mechanism plausibility, evidence strength, or safety profile. One hypothesis — mGlu2/3 modulation via psilocybin metabolites — survived with VIABLE verdict. That's the one worth lab time.
Research audit for psychedelics work.
Send one hypothesis, draft, or literature question. We run it through the adversarial pipeline and show you what survives.